A Phase 3 interventional study of Aripiprazole in Bipolar I Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 12 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-02-12.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the safety and efficacy of long-term administration of aripiprazole by performing extended administration of aripiprazole in combination with mood stabilizer (lithium or valproate) in an unblinded manner to those patients who completed the preceding multicenter, double-blind, placebo-controlled, parallel group-comparison trial of aripiprazole in patients with bipolar disorder experiencing a manic or mixed episode (Study 031-06-003, hereafter "Study 003") but whose condition worsened or remained unchanged or who discontinued Study 003 between Day 14 and Day 21 due to lack of drug efficacy.
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who were enrolled in and have completed or withdrawn from Study 003 and who meet the following criteria
Exclusion Criteria:
Subjects presenting with a clinical picture and/or history that is consistent with a diagnosis of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Aripiprazole
oral, 24mg(4 tablets)/day
Also known as: OPC-14597
Young Mania Rating Scale (YMRS)
YMRS is composed of 11 evaluation items with 5 rating levels each. Items rated on a scale of 0 to 4 (comprising 5 rating levels of one point each) are 1) levated mood, 2) increased motor activity/energy, 3) sexual interest, 4) sleep, 7) language-thought disorder, 10) appearance, and 11) insight. Items rated on a scale of 0 to 8 (comprising 5 rating levels of two points each) are 5) irritability, 6) speech (rate and amount), 8) content, and 9) disruptive-aggressive behavior. YMRS ranges from 0 (best possible outcome) to 60 (worst possible outcome). Using LOCF datasets, descriptive statistics of actual values for changes of YMRS total scores from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated.
Time frame: baseline (Day 1 of preceding study), Day 154 or at discontinuation
Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)
CGI-BP severity of illness is a scale for overall evaluation of the severity of bipolar disorder; it comprises 3 components-mania, depression, and overall bipolar illness. CGI-BP severity of illness score (mania) ranges form 1 (normal, not ill) to 7 (very severely ill). Using LOCF datasets, descriptive statistics of actual values for change of CGI-BP severity of illness score (mania) from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated for each treatment group.
Time frame: Baseline (Day 1 of preceding study) , Day 154 or at discontinuation
| Milestone | Aripiprazple |
|---|---|
| Started | 59 |
| Completed | 22 |
| Not completed | 37 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Physician decision | 7 |
| Withdrew: Protocol violation | 8 |
| Withdrew: Withdrawal by subject | 10 |
| Withdrew: Progression to depressive phase | 4 |
YMRS is composed of 11 evaluation items with 5 rating levels each. Items rated on a scale of 0 to 4 (comprising 5 rating levels of one point each) are 1) levated mood, 2) increased motor activity/energy, 3) sexual interest, 4) sleep, 7) language-thought disorder, 10) appearance, and 11) insight. Items rated on a scale of 0 to 8 (comprising 5 rating levels of two points each) are 5) irritability, 6) speech (rate and amount), 8) content, and 9) disruptive-aggressive behavior. YMRS ranges from 0 (best possible outcome) to 60 (worst possible outcome). Using LOCF datasets, descriptive statistics of actual values for changes of YMRS total scores from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated.
| scores on a scale | Aripiprazple |
|---|---|
| Young Mania Rating Scale (YMRS) | -18.3 ± 12.71 |
CGI-BP severity of illness is a scale for overall evaluation of the severity of bipolar disorder; it comprises 3 components-mania, depression, and overall bipolar illness. CGI-BP severity of illness score (mania) ranges form 1 (normal, not ill) to 7 (very severely ill). Using LOCF datasets, descriptive statistics of actual values for change of CGI-BP severity of illness score (mania) from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated for each treatment group.
| scores on a scale | Aripiprazple |
|---|---|
| Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania) | -2.4 ± 1.76 |
Collected over 22 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole | — | 2/56 (3.6%) | 37/56 (66.1%) |
| Event | Aripiprazole |
|---|---|
| HepatitisHepatobiliary disorders | 1/56 |
| HeadacheNervous system disorders | 1/56 |
| ManiaPsychiatric disorders | 1/56 |
| Event | Aripiprazole |
|---|---|
| Weight IncreasedInvestigations | 16/56 |
| AkathisiaNervous system disorders | 12/56 |
| TremorNervous system disorders | 10/56 |
| SomnolenceNervous system disorders | 8/56 |
| InsomniaPsychiatric disorders | 8/56 |
| NasopharyngitisInfections and infestations | 5/56 |
| HeadacheNervous system disorders | 5/56 |
| ConstipationGastrointestinal disorders | 4/56 |
| Salivary HypersecretionGastrointestinal disorders | 4/56 |
| VomitingGastrointestinal disorders | 4/56 |
Full Analysis Population(FAS):Excluding the following subjects from the randomized subjects: * 3 subjects with GCP violation * 1 subject whose post dose efficacy were not available
| Age, Continuous(years) | Arupiprazole |
|---|---|
| Mean | 34.5 ± 12.45 |
| Age, Categorical(Participants) | Arupiprazole |
|---|---|
| <=18 years | 3 |
| Between 18 and 65 years | 52 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Arupiprazole |
|---|---|
| Female | 28 |
| Male | 27 |
| Region of Enrollment(participants) | Arupiprazole |
|---|---|
| Taiwan | 5 |
| China | 17 |
| Japan | 11 |
| Malaysia | 6 |
| Indonesia | 4 |
| Philippines | 12 |
The record gives a start of Jan 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Co., Ltd. →